Smith Group Asset Management’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-9,520
| Closed | -$331K | – | 168 |
|
|
2025
Q4 | $331K | Buy |
9,520
+225
| +2% | +$17.7K | 0.02% | 158 |
|
|
2025
Q3 | $773K | Buy |
9,295
+276
| +3% | +$20K | 0.04% | 105 |
|
|
2025
Q2 | $662K | Hold |
9,019
| – | – | 0.04% | 114 |
|
|
2025
Q1 | $1.03M | Sell |
9,019
-6,389
| -41% | -$389K | 0.08% | 84 |
|
|
2024
Q4 | $776K | Buy |
15,408
+152
| +1% | +$7.96K | 0.06% | 101 |
|
|
2024
Q3 | $706K | Buy |
15,256
+3,081
| +25% | +$109K | 0.06% | 80 |
|
|
2024
Q2 | $396K | Buy |
12,175
+73
| +0.6% | +$2K | 0.04% | 100 |
|
|
2024
Q1 | $305K | Hold |
12,102
| – | – | 0.02% | 170 |
|
|
2023
Q4 | $393K | Buy |
+12,102
| New | +$332K | 0.02% | 142 |
|
|
2021
Q4 | – | Sell |
-27,422
| Closed | -$540K | – | 373 |
|
|
2021
Q3 | $540K | Sell |
27,422
-1,458
| -5% | -$30.5K | 0.03% | 128 |
|
|
2021
Q2 | $635K | Sell |
28,880
-265
| -0.9% | -$5.9K | 0.03% | 118 |
|
|
2021
Q1 | $693K | Sell |
29,145
-31,660
| -52% | -$845K | 0.04% | 97 |
|
|
2020
Q4 | $1.59M | Sell |
60,805
-9,270
| -13% | -$195K | 0.09% | 90 |
|
|
2020
Q3 | $1.22M | Sell |
70,075
-6,450
| -8% | -$103K | 0.06% | 95 |
|
|
2020
Q2 | $1.29M | Buy |
76,525
+2,169
| +3% | +$30.5K | 0.07% | 93 |
|
|
2020
Q1 | $884K | Buy |
74,356
+36,920
| +99% | +$457K | 0.05% | 96 |
|
|
2019
Q4 | $453K | Buy |
+37,436
| New | +$521K | 0.02% | 154 |
|
|
2018
Q4 | – | Sell |
-37,505
| Closed | -$526K | – | 454 |
|
|
2018
Q3 | $526K | Sell |
37,505
-59,360
| -61% | -$830K | 0.02% | 198 |
|
|
2018
Q2 | $1.52M | Sell |
96,865
-57,280
| -37% | -$996K | 0.04% | 145 |
|
|
2018
Q1 | $2.54M | Sell |
154,145
-100,491
| -39% | -$1.86M | 0.08% | 108 |
|
|
2017
Q4 | $4.6M | Sell |
254,636
-11,449
| -4% | -$207K | 0.14% | 101 |
|
|
2017
Q3 | $5.13M | Buy |
266,085
+1,990
| +0.8% | +$29.7K | 0.17% | 92 |
|
|
2017
Q2 | $3.12M | Buy |
264,095
+177,955
| +207% | +$1.93M | 0.1% | 132 |
|
|
2017
Q1 | $944K | Sell |
86,140
-30
| -0% | -$263 | 0.03% | 173 |
|
|
2016
Q4 | $626K | Buy |
+86,170
| New | +$675K | 0.02% | 176 |
|
|
2016
Q3 | – | Sell |
-30,080
| Closed | -$164K | – | 462 |
|
|
2016
Q2 | $164K | Buy |
30,080
+12,300
| +69% | +$64K | ﹤0.01% | 280 |
|
|
2016
Q1 | $83K | Buy |
17,780
+4,210
| +31% | +$16.4K | ﹤0.01% | 281 |
|
|
2015
Q4 | $68K | Buy |
+13,570
| New | +$61.2K | ﹤0.01% | 312 |
|
Other funds holding CORT
ISL
VPM
VCM
PA
Smith Group Asset Management's CORT Position: Q1 2026 in Review
Smith Group Asset Management sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 9,520 shares — an estimated $331K sold.
Smith Group Asset Management first reported a position in CORT in Q4 2015 and held it in 28 quarters. The position peaked at $5.13M in Q3 2017. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.
- Smith Group Asset Management reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
- Smith Group Asset Management sold 9,520 Corcept Therapeutics shares in Q1 2026, an estimated $331K.
- Smith Group Asset Management first reported a position in Corcept Therapeutics in Q4 2015 and held it in 28 quarters.
- Smith Group Asset Management's Corcept Therapeutics position peaked at $5.13M in Q3 2017.
- 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.
Based on Smith Group Asset Management's 13F filing for Q1 2026, filed 18 May 2026.